Core 1: Biobank and Pathology

核心 1：生物样本库和病理学

• 批准号: 10024075
• 负责人: ASIF RASHID
• 金额: $ 25.88万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-25 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10024075
• 关键词: Biological; Biopsy; Biopsy Specimen; Blood; Blood specimen; CLIA certified; Caring; Characteristics; Clinical; Clinical Informatics; Clinical Pathology; Clinical Trials; Collection; Consent; Core Biopsy; Custom; Data; Databases; Detection; Development; Ensure; Event; Fine needle aspiration biopsy; Freezing; Funding; Future; Goals; Grant; Histologic; Immunotherapy; In Situ Hybridization; Incidence; Institution; Institutional Review Boards; Liver; Liver neoplasms; Medical center; Molecular; Molecular Profiling; Operative Surgical Procedures; Paraffin Embedding; Pathologic; Pathologist; Pathology; Patients; Pattern; Plasma; Preparation; Prevention; Primary carcinoma of the liver cells; Procedures; Process; Protocols documentation; Quality Control; Reagent; Recurrence; Reproducibility; Research; Research Personnel; Research Project Grants; Resected; Resources; Sampling; Serum; Services; Slide; Specimen; Standardization; System; Testing; Texas; Tissue Banks; Tissue Sample; Tissues; Transact; Translational Research; Treatment outcome; Tumor Bank; Universities; University of Texas M D Anderson Cancer Center; Vital Status; biobank; clinical development; clinically relevant; demographics; innovation; molecular pathology; novel; novel therapeutics; prospective; quality assurance; relational database; repository; sample collection; success; time use; tumor; virtual

Core 1: Biobank and Pathology – SUMMARY/ABSTRACT The primary objective of the Biobank and Pathology Core (Core 1) is to facilitate innovative translational research in prevention, detection and treatment of HCC, by providing clinically and histologically well- characterized tissue and blood specimens from patients with HCC. Core 1 will serve as the comprehensive resource for the SPORE projects with an overall goal of centralizing the collection, storage and distribution of biospecimens; and gathering of histopathological/molecular profiles, and clinicopathological information of patients with hepatocellular carcinoma (HCC) who are referred to MD Anderson. Reflecting the rising incidence of HCC, the number of HCC patients who sought, and received, care at MD Anderson has increased every year, from 277 patients in 2013 to 580 patients in 2017, a 2-fold increase during the most recent 5 years. Core 1 will maintain a tissue and blood repository of HCC. The specimens included in this repository are: a) Fresh frozen tumor and adjacent liver tissues from surgically resected HCCs or from biopsy samples; b) Paraffin- embedded tumor and adjacent liver tissue from surgically-resected HCCs or from biopsy specimens; c) Blood samples (serum, plasma, buffy coat) from HCC patients; d) Core needle biopsy and fine needle aspirate specimens. Currently, 2618 tissue specimens from 219 HCC patients and blood specimens from 1824 HCC patients are available in the Liver Tumor Bank. During the duration of the HCC SPORE grant, Core 1 will continue to collect tissue and blood specimens, with the following anticipated numbers: resected tissue (200 patients), biopsies (75 patients) and blood samples (1000 patients). Core 1 will provide pathological review for all clinical specimens utilized in the SPORE projects and will provide histopathological services as necessary. In addition, Core 1 will create and maintain a database for all HCC specimens collected, using a customized database with modules for comprehensive sample identification, characterization, processing, sample/slide quality control, research tissue requests, sample transactions, and tracking of tissue samples. Finally, Core 1 will anticipate future needs and fill niches for which no reagents currently exist. These include: a) TMAs, b) Immuno-profiling of surgically-resected tumors and adjacent liver, and c) Development of novel, clinically- relevant CLIA-compliant tests.

核心1：生物样本库和病理学-总结/摘要 生物库和病理学核心（核心1）的主要目标是促进创新的翻译 通过提供临床和组织学良好的HCC预防、检测和治疗研究- 来自HCC患者的特征性组织和血液标本。核心1将作为 资源的SPORE项目的总体目标是集中收集，存储和分发 生物标本;收集组织病理学/分子特征和临床病理学信息 转诊至MD安德森的肝细胞癌（HCC）患者。反映了发病率的上升 在HCC患者中，寻求并接受MD安德森治疗的HCC患者数量每年都在增加。 从2013年的277例患者到2017年的580例患者，在最近5年内增加了2倍。核心 1将维持HCC的组织和血液储存库。本库中的标本包括：a）新鲜标本 来自手术切除的HCC或来自活检样品的冷冻肿瘤和邻近肝组织; B）石蜡- - 来自切除的HCC或来自活检标本的包埋的肿瘤和邻近的肝组织; 来自HCC患者的样本（血清、血浆、血沉棕黄层）; d）芯针活检和细针抽吸 标本目前，来自219名HCC患者的2618份组织标本和来自1824名HCC患者的血液标本 患者可在肝脏肿瘤库中获得。在HCC SPORE赠款期间，核心1将 继续收集组织和血液标本，预计数量如下：切除组织（200 患者）、活组织检查（75例患者）和血液样本（1000例患者）。核心1将提供病理学审查， SPORE项目中使用的所有临床标本，并将在必要时提供组织病理学服务。 此外，核心1将使用定制的 数据库，包含用于全面样品识别、表征、处理、样品/载玻片 质量控制、研究组织请求、样本交易和组织样本跟踪。核心1 将预测未来的需求，并填补目前没有试剂的空白。这些措施包括：a）TMA，B） 切除的肿瘤和邻近肝脏的免疫分析，和c）开发新的临床上可接受的免疫治疗。 相关CLIA合规测试。